Overview

Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis agents, antitumor vaccins, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.

Full Product Details

9780841237452

Table of Contents

Reviews

<br> These 19 articles were mostly drawn from the American Chemical Society's March 2000 symposium entitled New Prospects in Anticancer Agents for the 21st Century, organized by managing editor Ojima (chemistry, State U. of New York, Stonybrook). The material covers a range of topics including the National Cancer Institute's new paradigms for cancer drug discovery and development; various statins from marine natural products; new generation taxoids and other microtubule-interacting anticancer agents; the potentially tumor specific mechanism-based agents; inhibitors of signaling pathway; anti angiogenesis agents including matrix metalloproteinase inhibitors, VEGF inhibitors; Abl tyrosine kinase inhibitors that exhibit promise against chronic myeloid leukemia; antitumor vaccines; and tumor activated prodrugs combining monoclonal antibody and cytotoxic agents. --SciTech Book News<br>

These 19 articles were mostly drawn from the American Chemical Society's March 2000 symposium entitled New Prospects in Anticancer Agents for the 21st Century, organized by managing editor Ojima (chemistry, State U. of New York, Stonybrook). The material covers a range of topics including the National Cancer Institute's new paradigms for cancer drug discovery and development; various statins from marine natural products; new generation taxoids and other microtubule-interacting anticancer agents; the potentially tumor specific mechanism-based agents; inhibitors of signaling pathway; anti angiogenesis agents including matrix metalloproteinase inhibitors, VEGF inhibitors; Abl tyrosine kinase inhibitors that exhibit promise against chronic myeloid leukemia; antitumor vaccines; and tumor activated prodrugs combining monoclonal antibody and cytotoxic agents. --SciTech Book News<br>

<br> These 19 articles were mostly drawn from the American Chemical Society's March 2000 symposium entitled New Prospects in Anticancer Agents for the 21st Century, organized by managing editor Ojima (chemistry, State U. of New York, Stonybrook). The material covers a range of topics including the National Cancer Institute's new paradigms for cancer drug discovery and development; various statins from marine natural products; new generation taxoids and other microtubule-interacting anticancer agents; the potentially tumor specific mechanism-based agents; inhibitors of signaling pathway; anti angiogenesis agents including matrix metalloproteinase inhibitors, VEGF inhibitors; Abl tyrosine kinase inhibitors that exhibit promise against chronic myeloid leukemia; antitumor vaccines; and tumor activated prodrugs combining monoclonal antibody and cytotoxic agents. --SciTech Book News<p><br>

Author Information

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available